Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright cut their FY2030 EPS estimates for Sagimet Biosciences in a research report issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $2.09 for the year, down from their previous forecast of $2.28. HC Wainwright has a "Buy" rating and a $29.00 price objective on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.14) per share.
A number of other equities analysts have also recently issued reports on the company. Wall Street Zen cut Sagimet Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Canaccord Genuity Group cut their price objective on Sagimet Biosciences from $56.00 to $50.00 and set a "buy" rating on the stock in a research report on Friday. Wells Fargo & Company set a $27.00 target price on Sagimet Biosciences in a research note on Friday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Sagimet Biosciences in a research note on Thursday, October 15th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Sagimet Biosciences in a research report on Thursday, October 1st. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Sagimet Biosciences has an average rating of "Moderate Buy" and an average price target of $26.07.
View Our Latest Analysis on Sagimet Biosciences
Sagimet Biosciences Stock Performance
Shares of NASDAQ SGMT opened at $10.22 on Monday. The business's 50 day moving average price is $9.88 and its 200-day moving average price is $7.69. Sagimet Biosciences has a fifty-two week low of $4.50 and a fifty-two week high of $11.45. The company has a market cap of $635.28 million, a price-to-earnings ratio of -8.59 and a beta of 3.43.
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.05).
Hedge Funds Weigh In On Sagimet Biosciences
Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its holdings in Sagimet Biosciences by 15.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,238 shares of the company's stock worth $105,000 after purchasing an additional 1,500 shares during the period. Baird Financial Group Inc. raised its position in Sagimet Biosciences by 19.8% during the 2nd quarter. Baird Financial Group Inc. now owns 15,677 shares of the company's stock valued at $121,000 after purchasing an additional 2,591 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Sagimet Biosciences during the 3rd quarter valued at $31,000. Fulcrum Asset Management LLP purchased a new stake in shares of Sagimet Biosciences in the 3rd quarter worth $37,000. Finally, Profund Advisors LLC lifted its holdings in shares of Sagimet Biosciences by 36.1% in the 3rd quarter. Profund Advisors LLC now owns 19,737 shares of the company's stock worth $195,000 after buying an additional 5,234 shares during the period. 87.86% of the stock is currently owned by institutional investors.
About Sagimet Biosciences
(
Get Free Report)
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body's production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sagimet Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.
While Sagimet Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.